Intramedullary Bone Grafting for Tibial Fractures
Trial Summary
What is the purpose of this trial?
This study will examine if there is a difference between the time to full union between the control group and the study group. Each group will be composed of patients who have an open fracture in the mid tibia. Both groups will undergo primary fixation via reamed intramedulary nailing (IMN), a common treatment for tibia shaft fractures in adults. The study group will have a bone graft applied to the open cortex of the fracture. The bone graft will be composed of the intramedullary reamings, which are a byproduct produced when the intramedullary canal is reamed in preparation for insertion of the IMN.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the idea that Intramedullary Bone Grafting for Tibial Fractures is an effective treatment?
The available research shows that Intramedullary Bone Grafting for Tibial Fractures is effective. In a study of 132 patients with tibial shaft fractures treated with intramedullary nailing, 96% of the patients had good or fair results, with only one patient experiencing a lasting poor result. This suggests that the treatment is successful for most patients. Additionally, another study highlights that combining intramedullary nailing with bone grafting can effectively treat tibial fracture nonunion, which is when a fracture doesn't heal properly. These findings support the effectiveness of this treatment for tibial fractures.12345
What safety data is available for intramedullary bone grafting in tibial fractures?
The safety data for intramedullary bone grafting in tibial fractures includes findings from several studies. Reamed intramedullary nailing is effective for most tibial fractures, with a high union rate and minimal need for additional bone grafting in aseptic nonunions. Complications such as dropped hallux and postoperative compartment syndrome occurred in 0.8% and 1.6% of cases, respectively. Anterior knee pain was reported in 42% of patients, but nail removal did not alleviate symptoms in nearly half of these cases. There is a low incidence of intraoperative complications, such as medullary tube fractures. The SPRINT trial identified factors associated with adverse events within one year of surgery, providing further insights into safety considerations.12467
Is Intramedullary Bone Graft a promising treatment for tibial fractures?
Yes, Intramedullary Bone Graft is a promising treatment for tibial fractures. It is part of a well-established method called intramedullary nailing, which has shown very good results in healing tibial fractures. Most patients experience good recovery, and the treatment is effective for a wide range of fracture types.12348
Research Team
Rodolfo Zamora, MD
Principal Investigator
University of Louisville
Eligibility Criteria
Adults with a specific type of broken tibia (shinbone) called an open fracture, who can have the wound closed during initial surgery and are willing to follow up for 6-9 months. Not for those under 18, pregnant women, patients with certain bone conditions or fractures, or individuals with quadriplegia or paraplegia.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo irrigation and debridement of the open fracture, reamed intramedullary nailing, and primary wound closure. The intervention group also receives a bone graft on the exposed cortex of the tibial fracture.
Follow-up
Participants receive follow-up care with clinic visits and X-rays to monitor fracture union and functional outcomes.
Treatment Details
Interventions
- Intramedullary Bone Graft
Intramedullary Bone Graft is already approved in United States, European Union for the following indications:
- Open tibial shaft fractures
- Nonunion of tibial fractures
- Open tibial shaft fractures
- Nonunion of tibial fractures
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Louisville
Lead Sponsor